Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. D11659
Molecular Weight | 572.9 g/mol |
---|---|
Molecular Formula | C26H24ClN2Na2O6P |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 6 |
Rotatable Bond Count | 4 |
Exact Mass | 572.0855897 g/mol |
Monoisotopic Mass | 572.0855897 g/mol |
Topological Polar Surface Area | 122 Ų |
Heavy Atom Count | 38 |
Formal Charge | 0 |
Complexity | 828 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 1 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 3 |
China's leading API and intermediate manufacturer, offering CMO/CDMO services and exports to 70+ countries, enhancing global health.
China's leading API and intermediate manufacturer, offering CMO/CDMO services and exports to 70+ countries, enhancing global health.
About the Company : Shandong Chenghui Shuangda Pharmaceutical Co., Ltd. is specialized in R&D and production of APIs and advanced intermediates. With 22 years of production experience,the company has ...
Details:
SAMTASU is a prodrug of oral tolvaptan (generic name is tolvaptan sodium phosphate). A prodrug is a medication that is converted into an active drug in the human body following administration.
Lead Product(s): Tolvaptan Sodium Phosphate
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Samtasu
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 30, 2022
Lead Product(s) : Tolvaptan Sodium Phosphate
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Launch in Japan of SAMTASU® for IV Infusion, a V2 -Receptor Antagonist for the Treatment of Cardi...
Details : SAMTASU is a prodrug of oral tolvaptan (generic name is tolvaptan sodium phosphate). A prodrug is a medication that is converted into an active drug in the human body following administration.
Brand Name : Samtasu
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 30, 2022
Details:
SAMTASU is a prodrug of oral tolvaptan (generic - tolvaptan sodium phosphate). A prodrug is a medication that is converted into an active drug in the human body. Tolvaptan, discovered by Otsuka, is a novel compound, antagonist of vasopressin V2-receptor.
Lead Product(s): Tolvaptan Sodium Phosphate
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Samtasu
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 28, 2022
Lead Product(s) : Tolvaptan Sodium Phosphate
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Otsuka Obtains Approval in Japan for SAMTASU® for I.V. Infusion, a V2 -Receptor Antagonist for th...
Details : SAMTASU is a prodrug of oral tolvaptan (generic - tolvaptan sodium phosphate). A prodrug is a medication that is converted into an active drug in the human body. Tolvaptan, discovered by Otsuka, is a novel compound, antagonist of vasopressin V2-receptor.
Brand Name : Samtasu
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 28, 2022
ABOUT THIS PAGE
A Tolvaptan Sodium Phosphate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Tolvaptan Sodium Phosphate, including repackagers and relabelers. The FDA regulates Tolvaptan Sodium Phosphate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Tolvaptan Sodium Phosphate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Tolvaptan Sodium Phosphate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Tolvaptan Sodium Phosphate supplier is an individual or a company that provides Tolvaptan Sodium Phosphate active pharmaceutical ingredient (API) or Tolvaptan Sodium Phosphate finished formulations upon request. The Tolvaptan Sodium Phosphate suppliers may include Tolvaptan Sodium Phosphate API manufacturers, exporters, distributors and traders.
click here to find a list of Tolvaptan Sodium Phosphate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
Tolvaptan Sodium Phosphate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Tolvaptan Sodium Phosphate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Tolvaptan Sodium Phosphate GMP manufacturer or Tolvaptan Sodium Phosphate GMP API supplier for your needs.
A Tolvaptan Sodium Phosphate CoA (Certificate of Analysis) is a formal document that attests to Tolvaptan Sodium Phosphate's compliance with Tolvaptan Sodium Phosphate specifications and serves as a tool for batch-level quality control.
Tolvaptan Sodium Phosphate CoA mostly includes findings from lab analyses of a specific batch. For each Tolvaptan Sodium Phosphate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Tolvaptan Sodium Phosphate may be tested according to a variety of international standards, such as European Pharmacopoeia (Tolvaptan Sodium Phosphate EP), Tolvaptan Sodium Phosphate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Tolvaptan Sodium Phosphate USP).
LOOKING FOR A SUPPLIER?